Virginia Cancer Institute

Recent papers from Virginia Cancer Institute

1. E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cyclesCell Reports · 2026
2. Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell LymphomaBlood Advances · 2026
3. Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemiaCancer · 2026
4. High-grade astrocytoma with piloid features: a clinical and genomic analysis of prognostic factors using a large cohortNeuro-Oncology · 2026
5. Nationally Recruited Telehealth Group-Based Cognitive Behavioral Therapy for Insomnia in Patients with Primary Brain Tumors: A Randomized NIH ORBIT Phase IIc StudyNeuro-Oncology Advances · 2026
6. Single-cell profiling of peripheral blood mononuclear cells in diverse men with prostate cancer reveals a fatal disease-associated immune signatureCancer Immunology Research · 2026
7. The Vanguard Study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection testsContemporary Clinical Trials · 2026
8. Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansionCancer · 2026
9. The role of rurality and area-level disadvantage in lifestyle risk factors and psychological well-being among cancer survivors: findings from the 2021 NCI HINTS-SEERCancer Causes & Control · 2026
10. Abstract A012: USP11 links germinal center B-cell fate to adaptive immune crosstalk in immunized miceBlood Cancer Discovery · 2026
11. Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancerFrontiers in Oncology · 2026
12. Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.Journal of Clinical Oncology · 2026
13. MPOWER: A pilot trial among men with prostate cancer—Optimizing wellness by enhanced relief from hot flashes with acupuncture.Journal of Clinical Oncology · 2026
14. Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy.Journal of Clinical Oncology · 2026
15. Real-world survival outcomes of surgical patients with squamous cell carcinoma of unknown primary of the head and neck: A National Cancer Database analysis.Journal of Clinical Oncology · 2026
16. A retrospective analysis of tarlatamab outcomes and safety in a global multicenter electronic health record network (TriNetX) database.Journal of Clinical Oncology · 2026
17. Association of baseline microbiome and responders to immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT).Journal of Clinical Oncology · 2026
18. S2433: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced, or metastatic pancreatic adenocarcinoma.Journal of Clinical Oncology · 2026
19. Real-world trends in the evolving use of first-line therapy in metastatic castration-sensitive prostate cancer patients (mCSPC) in the United States.Journal of Clinical Oncology · 2026
20. National perspectives on artificial intelligence use in cancer care: Confidence, adoption, and barriers.Journal of Clinical Oncology · 2026